RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > 8 > Brexit Impact: EMA Suspends Publication of Clinical Trial Data

Brexit Impact: EMA Suspends Publication of Clinical Trial Data

Posted 15 August 2018 | By Zachary Brennan 

Brexit Impact: EMA Suspends Publication of Clinical Trial Data

As of 1 August, the European Medicines Agency (EMA) has suspended all new activities related to the publication of clinical data.

EMA said it will continue to publish clinical data submitted by the end of July but no new data packages will be processed until further notice.

“This is a result of the implementation of the third phase of EMA's business continuity plan to prepare for its relocation to the Netherlands,” the agency said.

EMA has stopped sending “invitation letters” and is contacting companies to cancel new submissions due after 1 August 2018. EMA will contact applicants prior to the restart of clinical data publication, once the relocation is complete, the agency added.

“By the end of October 2018, EMA will publish all clinical data submitted before 1 August 2018 (corresponding to regulatory procedures finalised in December 2016),” EMA noted.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe